S&P 500   4,026.35 (+1.39%)
DOW   32,702.34 (+0.95%)
QQQ   313.07 (+1.94%)
AAPL   160.93 (+2.08%)
MSFT   280.98 (+2.09%)
META   205.57 (+2.44%)
GOOGL   101.47 (+0.44%)
AMZN   100.29 (+3.14%)
TSLA   193.68 (+2.37%)
NVDA   270.24 (+2.32%)
NIO   9.83 (+6.85%)
BABA   99.95 (+1.58%)
AMD   96.32 (+1.86%)
T   19.00 (+1.50%)
F   12.06 (+3.97%)
MU   63.84 (+7.69%)
CGC   1.82 (+0.55%)
GE   94.09 (+1.02%)
DIS   96.90 (+2.19%)
AMC   5.00 (-2.91%)
PFE   40.21 (+0.55%)
PYPL   74.23 (+2.10%)
NFLX   332.01 (+2.62%)
S&P 500   4,026.35 (+1.39%)
DOW   32,702.34 (+0.95%)
QQQ   313.07 (+1.94%)
AAPL   160.93 (+2.08%)
MSFT   280.98 (+2.09%)
META   205.57 (+2.44%)
GOOGL   101.47 (+0.44%)
AMZN   100.29 (+3.14%)
TSLA   193.68 (+2.37%)
NVDA   270.24 (+2.32%)
NIO   9.83 (+6.85%)
BABA   99.95 (+1.58%)
AMD   96.32 (+1.86%)
T   19.00 (+1.50%)
F   12.06 (+3.97%)
MU   63.84 (+7.69%)
CGC   1.82 (+0.55%)
GE   94.09 (+1.02%)
DIS   96.90 (+2.19%)
AMC   5.00 (-2.91%)
PFE   40.21 (+0.55%)
PYPL   74.23 (+2.10%)
NFLX   332.01 (+2.62%)
S&P 500   4,026.35 (+1.39%)
DOW   32,702.34 (+0.95%)
QQQ   313.07 (+1.94%)
AAPL   160.93 (+2.08%)
MSFT   280.98 (+2.09%)
META   205.57 (+2.44%)
GOOGL   101.47 (+0.44%)
AMZN   100.29 (+3.14%)
TSLA   193.68 (+2.37%)
NVDA   270.24 (+2.32%)
NIO   9.83 (+6.85%)
BABA   99.95 (+1.58%)
AMD   96.32 (+1.86%)
T   19.00 (+1.50%)
F   12.06 (+3.97%)
MU   63.84 (+7.69%)
CGC   1.82 (+0.55%)
GE   94.09 (+1.02%)
DIS   96.90 (+2.19%)
AMC   5.00 (-2.91%)
PFE   40.21 (+0.55%)
PYPL   74.23 (+2.10%)
NFLX   332.01 (+2.62%)
S&P 500   4,026.35 (+1.39%)
DOW   32,702.34 (+0.95%)
QQQ   313.07 (+1.94%)
AAPL   160.93 (+2.08%)
MSFT   280.98 (+2.09%)
META   205.57 (+2.44%)
GOOGL   101.47 (+0.44%)
AMZN   100.29 (+3.14%)
TSLA   193.68 (+2.37%)
NVDA   270.24 (+2.32%)
NIO   9.83 (+6.85%)
BABA   99.95 (+1.58%)
AMD   96.32 (+1.86%)
T   19.00 (+1.50%)
F   12.06 (+3.97%)
MU   63.84 (+7.69%)
CGC   1.82 (+0.55%)
GE   94.09 (+1.02%)
DIS   96.90 (+2.19%)
AMC   5.00 (-2.91%)
PFE   40.21 (+0.55%)
PYPL   74.23 (+2.10%)
NFLX   332.01 (+2.62%)
NASDAQ:VTGN

VistaGen Therapeutics - VTGN Stock Forecast, Price & News

$0.14
0.00 (-0.79%)
(As of 03/29/2023 03:52 PM ET)
Add
Compare
Today's Range
$0.14
$0.15
50-Day Range
$0.13
$0.30
52-Week Range
$0.08
$1.79
Volume
1.98 million shs
Average Volume
6.34 million shs
Market Capitalization
$30.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VistaGen Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.15mentions of VistaGen Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.26) to ($0.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.09 out of 5 stars

Medical Sector

983rd out of 999 stocks

Pharmaceutical Preparations Industry

482nd out of 489 stocks


VTGN stock logo

About VistaGen Therapeutics (NASDAQ:VTGN) Stock

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Stock News Headlines

Modern Day Options Trading For Beginners!
These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. pixel
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Here's what Wall Street expects from VistaGen Therapeutics's earnings
Preview: VistaGen Therapeutics's Earnings
VTGN VistaGen Therapeutics, Inc.
Vistagen to Acquire Pherin Pharmaceuticals
See More Headlines
Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Company Calendar

Last Earnings
2/07/2023
Today
3/29/2023
Fiscal Year End
3/31/2023
Next Earnings (Estimated)
6/22/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTGN
Employees
31
Year Founded
N/A

Profitability

Net Income
$-47,760,000.00
Net Margins
-5,614.37%
Pretax Margin
-5,613.99%

Debt

Sales & Book Value

Annual Sales
$1.11 million
Book Value
$0.31 per share

Miscellaneous

Free Float
210,531,000
Market Cap
$30.53 million
Optionable
Not Optionable
Beta
1.09

Key Executives

  • Shawn K. Singh
    Chief Executive Officer & Director
  • Jerrold D. Dotson
    Chief Financial Officer, Secretary & VP
  • Ellis Wilson
    Vice President-Global Clinical Operations
  • Jessica R. Haskell
    Vice President & Associate General Counsel
  • Ann Cunningham
    Director & Chief Commercial Officer













VTGN Stock - Frequently Asked Questions

Should I buy or sell VistaGen Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VTGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTGN, but not buy additional shares or sell existing shares.
View VTGN analyst ratings
or view top-rated stocks.

How have VTGN shares performed in 2023?

VistaGen Therapeutics' stock was trading at $0.1030 at the beginning of 2023. Since then, VTGN shares have increased by 34.1% and is now trading at $0.1381.
View the best growth stocks for 2023 here
.

When is VistaGen Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 22nd 2023.
View our VTGN earnings forecast
.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings results on Tuesday, February, 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The firm earned $0.18 million during the quarter, compared to analysts' expectations of $0.31 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 158.24% and a negative net margin of 5,614.37%.

What ETF holds VistaGen Therapeutics' stock ?

Psyk Etf holds 77,466 shares of VTGN stock, representing 0.60% of its portfolio.

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Ayala Pharmaceuticals (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (2.32%), Geode Capital Management LLC (1.49%), Two Sigma Investments LP (0.30%), MAI Capital Management (0.30%), Alliancebernstein L.P. (0.14%) and GPS Wealth Strategies Group LLC (0.12%). Insiders that own company stock include H Ralph Snodgrass, Jerrold Duane Dotson, Jerry B Gin, Reid G Adler, Shawn Singh and Venrock Healthcare Capital Par.
View institutional ownership trends
.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.14.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics (NASDAQ:VTGN) has a market capitalization of $30.29 million and generates $1.11 million in revenue each year. The company earns $-47,760,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.vistagen.com. The company can be reached via phone at (650) 577-3600, via email at ir@vistagen.com, or via fax at 888-482-2602.

This page (NASDAQ:VTGN) was last updated on 3/29/2023 by MarketBeat.com Staff